<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03927989</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00068951</org_study_id>
    <nct_id>NCT03927989</nct_id>
  </id_info>
  <brief_title>Tobacco Treatment in the Context of Lung Cancer Screening</brief_title>
  <official_title>Tobacco Treatment in the Context of Lung Cancer Screening</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of South Carolina</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of South Carolina</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed study will test a medication plus text messaging intervention specifically
      designed for lung cancer screening patients. Half of the patients will receive standard of
      care, and half will receive the treatment intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Screening for lung cancer at earlier, more treatable stages has the potential to reduce
      mortality from the U.S.'s most deadly cancer. Annual lung cancer screening with low-dose
      computed tomography is now recommended for high risk individuals based on age and smoking
      history. This study will evaluate a smoking cessation intervention for lung cancer screening
      patients. We will evaluate quit rates after a standard intervention (brief counseling session
      at time of lung cancer screening) versus a dual nicotine replacement therapy (NRT) and
      gain-framed text messaging intervention.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>End of Treatment Abstinence Rates</measure>
    <time_frame>Week 8 (end of treatment)</time_frame>
    <description>7-day point prevalence abstinence rates</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>End of Study Abstinence Rates</measure>
    <time_frame>3-month follow-up</time_frame>
    <description>Effect size estimates at End of Study</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Smoking Cessation</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Advice to quit and brief discussion of tobacco use plus dual nicotine replacement therapy plus 8 weeks of gain-framed text messages tailored to lung cancer screening patients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Advice to quit and brief discussion of tobacco use</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Text messaging plus nicotine replacement therapy</intervention_name>
    <description>Brief advice to quit smoking prior to lung cancer screening (LCS), 8 weeks of gain-framed, LCS-tailored text messages, and nicotine replacement therapy.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Care at Lung Cancer Screening</intervention_name>
    <description>Brief advice to quit smoking prior to lung cancer screening</description>
    <arm_group_label>Standard Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          1. 55 years or older

          2. 30 pack year history of smoking

          3. current smoker (defined as breath carbon monoxide&gt;6ppm)

          4. willing to be randomized

          5. English speaking

        Exclusion:

          1. unstable psychiatric/medical conditions such as suicidal ideation, acute psychosis,
             severe alcohol dependence, substance abuse, or dementia

          2. in the immediate (within 2 weeks) post myocardial infarction period

          3. serious arrhythmias

          4. unstable angina pectoris

          5. hemodynamically or electrically unstable

          6. currently taking part in any other tobacco treatment program or using cessation
             medication (i.e., taking NRT or other cessation medications, enrolled in the Quitline,
             in another drug study).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alana Rojewski, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Alana Rojewski, PhD</last_name>
    <phone>7407045853</phone>
    <email>rojewski@musc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alana Rojewski, PhD</last_name>
      <phone>843-876-1593</phone>
      <email>rojewski@musc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 23, 2019</study_first_submitted>
  <study_first_submitted_qc>April 23, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2019</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nicotine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

